.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Poster
P 234

The host-targeted MEK1/2-inhibitor ATR-002 (Zapnometinib) acts antiviral against SARS-CoV-2 and synergistically potentiates the antiviral effect of direct-acting anti-SARS-CoV-2 drugs

Appointment

Date: 28/03/2023

Time: 13:00 – 13:00

Talk time: 0 Min.

Discussion time: 0 Min.

Location / Stream:

SARS-CoV-2

Session

SARS-CoV-2

Topics

Host cell factors and modulation
SARS-CoV-2

Authors

Benjamin Ambrosy (Muenster / DE), Dr. André Schreiber (Muenster / DE), Prof. Dr. Oliver Planz (Tuebingen / DE), Dr. Sebastian Schloer (Muenster / DE; Hamburg / DE), Prof. Dr. Ursula Rescher (Muenster / DE), Prof. Dr. Stephan Ludwig (Muenster / DE)